Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
A phase 1/2 trial of Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) in nasopharyngeal carcinoma, run by PT. Prodia Stem Cell Indonesia, active and no longer recruiting.
Overview
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer is a phase 1/2 interventional study registered as NCT05261750 by PT. Prodia Stem Cell Indonesia, with 15 participants enrolled, started 2022-04-30 and due to reach its primary completion in 2026-02-28. Interventions recorded: Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) and Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy).
Similar pages
not linked directly; found by shared links- TrialA Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Shares Nasopharyngeal carcinoma and the tag pipeline.
- TrialAVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Shares Nasopharyngeal carcinoma and the tag pipeline.
- TreatmentHMBD-001
Shares Nasopharyngeal carcinoma and the tag pipeline.
- TreatmentKL-A167
Shares Nasopharyngeal carcinoma and the tag pipeline.
- TreatmentMRG003
Shares Nasopharyngeal carcinoma and the tag pipeline.
- TreatmentYL201
Shares Nasopharyngeal carcinoma and the tag pipeline.